Cybin Inc. (OTCMKTS:CYBN - Get Free Report) fell 2.6% on Monday . The stock traded as low as $7.26 and last traded at $7.26. 228,100 shares traded hands during mid-day trading, a decline of 27% from the average session volume of 313,547 shares. The stock had previously closed at $7.45.
Cybin Price Performance
The firm has a fifty day moving average price of $7.89 and a two-hundred day moving average price of $7.69. The stock has a market capitalization of $167.96 million, a PE ratio of -37.47 and a beta of 0.68.
About Cybin
(
Get Free Report)
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Featured Articles
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
